Human FGFR3 Extracellular Domain (recombinant)

<strong>Human FGFR3 Extracellular Domain (recombinant)</strong>_x000D_ <strong>Catalog number:</strong> B2016757_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 39.6 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> ACH, CD333, Fibroblast Growth Factor Receptor 3_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Klag KA, Horton WA. Advances in treatment of achondroplasia and osteoarthritis Hum Mol Genet. 2016 Apr 15;25(R1):R2-8._x000D_ 2: Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, Saenz P, Martínez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation Clin Cancer Res. 2005 Sep 1;11(17):6280-90._x000D_ 3: Gorbenko O, Ovcharenko G, Klymenko T, Zhyvoloup O, Gaman N, Volkova D, Gout I, Filonenko V. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3 Hybridoma (Larchmt). 2009 Aug;28(4):295-300._x000D_ 4: Keegan K, Johnson DE, Williams LT, Hayman MJ. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3 Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1095-9._x000D_ 5: McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer Cancer Discov. 2012 Feb;2(2):156-71._x000D_ 6: Webster MK, Donoghue DJ. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain Mol Cell Biol. 1997 Oct;17(10):5739-47._x000D_ 7: Gorbenko O, Ovcharenko G, Volkova D, Mayilo D, Gaman N, Khozhayenko Y, Usenko V, Gout I, Filonenko V. Monoclonal antibodies with selective specificity towards different glycosylation isoforms of FGFR1 Hybridoma (Larchmt). 2009 Aug;28(4):287-93._x000D_ 8: Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia Nat Genet. 1996 Jun;13(2):233-7._x000D_ 9: Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7894-9._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/9438390">10: d'Avis PY, Robertson SC, Meyer AN, Bardwell WM, Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I Cell Growth Differ. 1998 Jan;9(1):71-8.</a>_x000D_ _x000D_ <strong>Products Related to Human FGFR3 Extracellular Domain (recombinant) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>